Bruce Neal's Publications

Tye SC, Jongs N, Coca SG et alii
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Journal articles
2022
Cardiovascular Diabetology
Crosby S, Rajadurai E, Jan S et alii
The effects of government policies targeting ethics and governance processes on clinical trial activity and expenditure: a systematic review
Journal articles
2022
Humanities and Social Sciences Communications
Baigent C, Emberson JR, Haynes R et alii
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Journal articles
2022
The Lancet
Sarraju A, Bakris G, Cannon CP et alii
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Journal articles
2022
Journal of the American College of Cardiology
Koshino A, Schechter M, Sen T et alii
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Journal articles
2022
Diabetes Care
Eyles H, Grey J, Jiang Y et alii
A sodium reduction smartphone app and reduced sodium salt for adults with hypertension: Findings from the SALTS randomized controlled trial (Preprint)
Preprints
2022
http://dx.doi.org/10.2196/preprints.43675
Neuen B, Fletcher R, Arnott C et alii
CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL
Conference Papers
2022
in NEPHROLOGY
Arnott C, Fletcher RA, Neal B
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Journal articles
2022
Heart Failure Clinics
Yin X, Rodgers A, Perkovic A et alii
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis
Journal articles
2022
Heart
Marklund M, Tullu F, Thout SR et alii
Estimated Benefits and Risks of Using a Reduced-Sodium, Potassium-Enriched Salt Substitute in India: A Modeling Study
Journal articles
2022
Hypertension
Maganja D, Trieu K, Reading M et alii
Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension – the SaltSwitch Online Grocery Shopping randomized trial
Journal articles
2022
American Heart Journal
Sen T, Koshino A, Neal B et alii
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
Journal articles
2022
Diabetes
Li C, Yu J, Hockham C et alii
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Journal articles
2022
Diabetes
Nadkarni GN, Takale D, Neal B et alii
A Post Hoc Analysis of KidneylntelX and Cardiorenal Outcomes in Diabetic Kidney Disease
Journal articles
2022
KIDNEY360
Liu Y, Xiao S, Yin X et alii
Nation-Wide Routinely Collected Health Datasets in China: A Scoping Review
Journal articles
2022
Public Health Reviews
Crosby S, Rajadurai E, Jan S et alii
The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review
Journal articles
2022
PLoS ONE
Haghdoost F, Gnanenthiran S, Shan S et alii
The effect of salt substitution on headache: a cluster-randomized controlled trial
Conference Papers
2022
in CEPHALALGIA
Tye S, Jong N, Coca SG et alii
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure
Conference Papers
2022
in DIABETOLOGIA
Schechter M, Koshino A, Jongs N et alii
Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis
Conference Papers
2022
in DIABETOLOGIA
Nazarzadeh M, Bidel Z, Canoy D et alii
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Journal articles
2022
The Lancet Diabetes and Endocrinology
Wu JHY, Trieu K, Coyle D et alii
Testing the Feasibility and Dietary Impact of a "Produce Prescription" Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia
Journal articles
2022
JOURNAL OF NUTRITION
Li JW, Arnott C, Heerspink HJL et alii
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Journal articles
2022
Journal of the American Heart Association
Ferrannini E, Baldi S, Scozzaro T et alii
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Journal articles
2022
Diabetes Care
Canoy D, Copland E, Nazarzadeh M et alii
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials
Journal articles
2022
Heart (British Cardiac Society)
Juraschek SP, Wang D, McEvoy JW et alii
Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE
Journal articles
2022
International Journal of Cardiology
Liao J, Kang A, Xia C et alii
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Journal articles
2022
Diabetes and Metabolism

Bruce Neal's Publications

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

The effects of government policies targeting ethics and governance processes on clinical trial activity and expenditure: a systematic review

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

A sodium reduction smartphone app and reduced sodium salt for adults with hypertension: Findings from the SALTS randomized controlled trial (Preprint)

CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis

Estimated Benefits and Risks of Using a Reduced-Sodium, Potassium-Enriched Salt Substitute in India: A Modeling Study

Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension – the SaltSwitch Online Grocery Shopping randomized trial

Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial

Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

A Post Hoc Analysis of KidneylntelX and Cardiorenal Outcomes in Diabetic Kidney Disease

Nation-Wide Routinely Collected Health Datasets in China: A Scoping Review

The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review

The effect of salt substitution on headache: a cluster-randomized controlled trial

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure

Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Testing the Feasibility and Dietary Impact of a "Produce Prescription" Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE

The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country